Deal-Making
For In Vivo's 17th annual Deals of the Year contest, we selected 12 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.
In the latest episode of the In Vivo podcast, Citeline’s expert panel of reporters and analysts unpack the biggest deals, trends and innovations following the J.P. Morgan Healthcare Conference.
Ten $1bn+ alliances were penned in January, and two exceeded $2bn.
An interactive look at pharma, medtech and diagnostics deals made during January 2025. Data courtesy of Biomedtracker.
In September last year, J&J lost a court case surrounding its 2019 purchase of Auris health, and was ordered to pay over $1bn in damages. Reactions to the potentially precedent-setting news were harsh and quick. In Vivo spoke to legal, M&A and BD experts from across the medtech industry to learn more about the true impacts.
Now that one of the most controversial pharma M&As of 2024 has closed, did overtures to concerned customers and extended prenotification discussions help Novo and Catalent seal the deal?
It’s time for In Vivo's 17th annual Deals of the Year contest. We've chosen 12 nominees across three categories – Top M&A, Top Alliance, and Top Financing – and now it’s your turn to pick the winners.
An interactive look at pharma, medtech and diagnostics deals made during December 2024. Data courtesy of Biomedtracker.
Nine $1bn+ alliances were penned in December, and two exceeded $2bn.
As we enter 2025, In Vivo convened a group of biotech executives for a wide-ranging conversation about dealmaking this year and the challenges and opportunities for companies in the cardiometabolic, longevity, radiopharmaceuticals and cancer spaces. Essential listening before JPM.
Six $1bn+ alliances were penned in November, and three exceeded $2bn.
An interactive look at pharma, medtech and diagnostics deals made during August 2024. Data courtesy of Biomedtracker.
Attrition among biotechs and VCs holding onto their reserve capital for existing investments may have reduced the capital available for new life sciences funding, but UK-based LifeArc Ventures believes its recent activity is indicative of a general upswing.
Nine biopharma companies made 12 or more deals, with Novartis inking 21 deals and leading M&A activity. Roche, meanwhile, spent little up front but maintained a hectic pace with 12 alliances.
Ten $1bn+ alliances were penned in October, and three exceeded $2bn.
An interactive look at pharma, medtech and diagnostics deals made during August 2024. Data courtesy of Biomedtracker.
During Q3, biopharmas brought in an aggregate $17bn in financing and device company fundraising totaled $3bn; while in vitro diagnostic firms and research tools players raised $1.1m.
While big pharma has significantly higher R&D and acquisition expenditures, certain biotechs have outperformed in terms of ROI and have substantial potential for future growth with their strong pipeline assets.
An interactive look at pharma, medtech and diagnostics deals made during August 2024. Data courtesy of Biomedtracker.
Fusion Pharmaceuticals Inc CEO John Valliant talked to In Vivo about Canadian leadership in radiopharmaceutical innovation, its differentiated approach, and excitement around combination therapies for precision cancer treatments.